Cybersecurity firm check point plans $1.5b 0.00% convertible senior notes due 2030, with an extra $225m option, to fund capped calls, buybacks and growth. Altrubio has roared back after another pivot in its twisty history, securing up to $225 million in series b funding to take an immune checkpoint enhancer through a midphase ulcerative colitis program. Proceeds will go toward buying back as much as $225 million of stock, the company said in a statement
Citigroup inc., jpmorgan chase & co Top news and commentary for technology's leaders, from all around the web. And morgan stanley are managing the offering, the.
